Mifanertinib Maleate

马来酸美凡厄替尼

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameMifanertinib Maleate
Drug Alias Namemifanertinib迈华替尼Mefatinib美凡厄替尼迈瑞东 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR L858R inhibitorsEGFR T790M inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2EGFR 19del +[5] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2025/10/21
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Maitai Bio-Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesSuzhou Maitai Bio-Technology Co LtdHangzhou Huadong Medicine Group Biotechnology Institute Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A